INTRAVENOUS ZOLEDRONIC ACID IN PREVENTING SUBSEQUENT OSTEOPOROTIC FRACTURES

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是确定在2年的时间内，在急性髋部骨折手术修复后给予名为唑来膦酸（一种双膦酸盐）加维生素D2、维生素D和元素碳酸钙的研究药物，与单独给予维生素D2、维生素D和元素碳酸钙相比，是否更有效地降低所有后续骨折的发生率。本研究还将尝试确定唑来膦酸对生活质量、日常生活体力活动、身体疼痛和医疗费用的影响（探索性终点）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an investigational drug with the name zoledronic acid, (a bisphosphonate) plus, vitamin D2, vitamin D and elemental calcium carbonate given after surgical repair on an acute hip fracture, is more effective in reducing the rate of all subsequent bone fractures compared to vitamin D2, vitamin D and elemental calcium carbonate alone, during a two year period of time. This study will also attempt to determine the effect of zoledronic acid on quality of life, physical activities of daily living, body pain, and medical costs (exploratory endpoints).